Skip to main content
. 2012 Aug 17;2(4):243–250. doi: 10.1159/000341725

Table 2.

Recent meta-analyses involving the effect of collaborative care teams including pharmacists on cardiovascular and renal outcomes

Ref. Disease state Number of trials (patient number) included in the meta-analysis Cardiovascular and renal outcomes
14 Heart failure 12 randomized controlled trials (n = 2,060)

  • All-cause hospitalizations: odds ratio 0.71 (95% CI 0.54–0.94)1;

  • Heart failure hospitalizations: odds ratio 0.69 (95% CI 0.51– 0.94)1
21 Hyperlipidemia 7 randomized controlled trials (n = 924) LDL weighted mean difference: −13.4 mg/dl (95% CI −23.0 to −3.8)1
21 Hypertension 19 randomized controlled trials (n = 10,479) Systolic BP weighted mean difference: −8.1 mm Hg (95% CI −10.2 to −5.9)1
22 Diabetes 14 randomized controlled trials (n = 2,073)

  • Hemoglobin A1C weighted mean difference: −0.76% (95% CI −1.06 to −0.47)1;

  • Fasting blood glucose weighted mean difference: −29.32 mg/dl (95% CI −39.54 to −19.10)1
29 CKD 8 controlled trials (n = 688 total: 47 transplants, 294 CKD, and 347 hemodialysis patients)

  • Mean all-cause hospitalizations (SD): 1.8 (2.4) vs. 3.1 (3.0), p = 0.021;

  • Incidence of ESRD or death in patients with diabetic nephropathy: 14.8 vs. 28.2 per 100 patient-years, adjusted relative risk 60%, p < 0.0011;

  • Patients at goal hemoglobin: 69.8 vs. 43.9%, p < 0.00012;

  • Patients at goal transferrin saturation: 64.8 vs. 40.4%, p = 0.0432;

  • Mean systolic BP (SD): 145.3 (16.8) vs. 175.8 (33.9) mm Hg, p = 0.0292;

  • Mean calcium-phosphate product (SD): 4.43 (1.20) vs. 4.80 (0.51) mmol2/l2, p = 0.042
1

Outcomes which were reduced by team-based care versus usual care.

2

Managements which were improved by team-based care versus usual care.